Securities code: 688575 securities abbreviation: Shenzhen Yhlo Biotech Co.Ltd(688575) Announcement No.: 2022-023 Shenzhen Yhlo Biotech Co.Ltd(688575)
Announcement of 2021 annual performance express
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
The main financial data of 2021 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm. The specific data are subject to the company’s regular report of 2021, and investors are reminded of investment risks. 1、 Main financial data and indicators in 2021
Unit: 10000 yuan
Increase or decrease range items in the same period of last year in the current reporting period
（％）
Total operating income 118944.22 99900.70 19.06
Operating profit 23574.67 24656.70 -4.39
Total profit 23520.65 24150.25 -2.61
Owned by the parent company
Net profit of investors 20855.01 21053.25 -0.94
Owned by the parent company
Net profit after deducting non recurring profit and loss of 18470.10, 18752.70 -1.51
Basic earnings per share (yuan) 0.54 0.58 -6.90
The weighted average net asset income decreased by 13.63 percentage points, with an interest rate of 17.54% and 31.17%
Increase / decrease range at the end of the reporting period at the beginning of the reporting period
（％）
Total assets 210845.49 132342.23 59.32
Assets attributable to the parent company
Owner’s equity 152014.80 76779.15 97.99
Share capital 40500.00 36400.00 11.26
Owned by the parent company
The net assets per share of the company are 3.75 2.11 77.73 yuan
Note: 1 The beginning amount of this report is the same as the end amount of the previous year legally disclosed.
2. The above financial data and indicators are filled in with the unaudited consolidated statement data, and the final results are subject to the company’s 2021 annual report.
2、 Description of operating performance and financial status
(I) operating conditions, financial conditions and main factors affecting operating performance
During the reporting period, the company achieved an operating revenue of 1189442200 yuan, a year-on-year increase of 190.4352 million yuan, an increase of 19.06%. This is mainly due to the overall recovery of China’s economy, the gradual increase of instrument installed capacity and terminal consumption, and the business income of self-produced chemiluminescence products in China was 543551000 yuan, a year-on-year increase of 191363500 yuan, an increase of 54.34%.
During the reporting period, the net profit attributable to the shareholders of the listed company was 2085501 million yuan, a year-on-year decrease of 0.94%, which was mainly affected by the following factors: (1) the overseas covid-19 business was affected by market competition and changes in product sales structure, resulting in a decline in gross profit margin; (2) Overseas non covid-19 businesses were affected by the epidemic, and the operating revenue and gross profit margin declined; (3) Due to the continuous increase of R & D efforts and market development resource investment, R & D expenses and sales expenses increased greatly.
At the end of the reporting period, the company’s total assets amounted to 2108454900 yuan, a year-on-year increase of 59.32%; The owner’s equity attributable to the shareholders of the listed company was 152.0148 million yuan, a year-on-year increase of 97.99%.
(II) the main reasons for the increase and decrease of relevant items in the above table with a range of more than 30%
At the end of the reporting period, the total assets, owner’s equity attributable to the parent company and net assets per share attributable to the owner of the parent company increased significantly, mainly due to the company’s listing on the science and innovation board and the availability of raised funds during the reporting period; This reason also led to a decline in the weighted average return on net assets.
3、 Risk tips
This performance express is the preliminary accounting result of the company’s financial department. It has not been audited by an accounting firm, and may be different from the final data disclosed in the annual report. The specific data will be disclosed in detail in the 2021 annual report.
It is hereby announced.
Shenzhen Yhlo Biotech Co.Ltd(688575) board of directors February 19, 2022
